Navigation Links
ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
Date:9/21/2010

ly held. For more information, please refer to www.chemocentryx.com.

Certain statements in this press release may constitute "forward-looking statements". These statements are made on the basis of current expectations, forecasts and assumptions that involve risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors outside of our control, that may cause our business, strategy or actual results to differ materially from those expressed or implied. We do not intend, and undertake no obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Spherix Reports Second Quarter Earnings
11. Tapestry Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 P&S Market ... market overview, trends, DRO analysis, market segmentation, ... developments, competitive scenario and top competitor profiles ... Market Development and Demand Forecast to 2020  ... Explore more about global biosensors ...
(Date:7/30/2015)... , July 30, 2015   Gaumard® Scientific ... to UNI®, the world,s first operating system to ... now available exclusively to Gaumard users. UNI® version ... launched Newborn Tory™ S2200, as well as improvements ... of clinical measures such as EtCO 2 .  ...
(Date:7/30/2015)... VIEJO, Calif. , July 30, 2015 /PRNewswire/ ... aspiring to eliminate all preventable hospitalization, recently received ... that its Remote Patient Intelligence (RPI) solution meets ... the FDA intends to exercise "Enforcement Discretion." ... "are not subject to further FDA regulatory requirements ...
Breaking Medicine Technology:Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 2FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 3
(Date:7/31/2015)... ... July 31, 2015 , ... The Mount Sinai Health System will work with ... potential of related, experimental treatments. The collaboration moves into the next phase with the ... one of five state licenses to produce and dispense medical marijuana. , Mount ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently, ZKB ... of Ohio, Western Division (Case No. 3:15-cv-00397) involving the Implanon® contraceptive implant ... spontaneous migration of their Implanon® implants, inability to locate the implants, unsuccessful and ...
(Date:7/31/2015)... ... July 31, 2015 , ... Florida ... novel catheter that was developed for targeted delivery of fluids to selected sites ... treated at Florida Hospital Tampa with the device that provides direct, local delivery ...
(Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 hair ... that they are the latest recipients of the Center of Clinical Excellence for ... the worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair Restoration ...
(Date:7/31/2015)... ... July 31, 2015 , ... Healthpointe ... a newly redesigned website at Healthpointe.net. The new website will feature a sleek ... The redesign serves to provide smoother interactions between patients and the Healthpointe clinics ...
Breaking Medicine News(10 mins):Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Healthpointe Announces Newly Redesigned Website 2
... ... been developed. Experienced weight loss physicians have raised the HCG diet caloric daily allowance from ... diet protocol written 50 years ago. The physician’s goal with this new HCG diet protocol ... patients. , ...
... ... place on May 6, 2010. Two years in the planning and development, the cutting-edge ... nonsurgical laser treatments for varicose veins and spider veins. , ... Prescott, AZ (PRWEB) April 27, 2010 -- Prescott Vein Specialties ...
... with chronic kidney disease have more severe anemia than white ... a multicenter study led by Johns Hopkins Children,s Center to ... Journal of Kidney Disease . The findings suggest that ... may be at play, raising the question whether current guidelines ...
... studies finds that patients, research participants and journal readers ... disclosed, in part because those financial ties may influence ... the April 26 issue of Archives of Internal ... ties to the pharmaceutical, biotechnology and medical device industries ...
... ─ Tiny, melanin-covered nanoparticles may protect bone marrow from ... at Albert Einstein College of Medicine of Yeshiva University ... these particles into human patients may hold promise in ... issue of the International Journal of Radiation Oncology, ...
... are most likely to be good candidates upon death, ... U.S. researchers have developed a new tool that may ... donors, a development that could potentially boost organ donation ... often good candidates for organ donation when they die ...
Cached Medicine News:Health News:Breakthrough in HCG Weight Loss Therapy 2Health News:Breakthrough in HCG Weight Loss Therapy 3Health News:New Varicose Vein Treatment Center Opens in Prescott, Arizona 2Health News:Anemia tougher to tackle in black children with kidney disease 2Health News:Patients, clinicians favor disclosure of financial ties to industry 2Health News:Patients, clinicians favor disclosure of financial ties to industry 3Health News:Novel nanoparticles prevent radiation damage 2Health News:Novel nanoparticles prevent radiation damage 3Health News:Novel nanoparticles prevent radiation damage 4Health News:Test Spots Potential Organ Donors Among Coma Patients 2
The RapidBARBITURATE test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of barbiturates and in human urine specimens above a cut-off level of 3...
... With membrane parasite ... and cytoplasm as antigen. ... different antigens than the ... possible to use two ...
Elisa test for qualitative detection of Total antibodies to Trypanosoma Cruzi in human serum or plasma....
Silicone ICD lead...
Medicine Products: